Log in

NYSE:ZOMZomedica Pharmaceuticals Corp (NYSEAMERICAN) Stock Price, Forecast & News

$0.21
-0.01 (-3.68 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.20
Now: $0.21
$0.22
50-Day Range
$0.13
MA: $0.18
$0.27
52-Week Range
$0.11
Now: $0.21
$0.50
Volume14.61 million shs
Average Volume16.91 million shs
Market Capitalization$23.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.09
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone734-369-2555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.09) per share

Profitability

Net Income$-19,780,000.00

Miscellaneous

EmployeesN/A
Market Cap$23.21 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions

How has Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock been impacted by COVID-19 (Coronavirus)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock was trading at $0.2078 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZOM shares have increased by 3.4% and is now trading at $0.2148. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) released its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings history.

Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?

Press coverage about ZOM stock has trended very positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a news impact score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutZomedica Pharmaceuticals Corp (NYSEAMERICAN).

Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) investors own include Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Acasti Pharma (ACST), Amarin (AMRN), Anavex Life Sciences (AVXL), Clearside Biomedical (CLSD), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the following people:
  • Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
  • Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
  • Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
  • Mr. Bruk Herbst, Chief Commercial Officer (Age 49)

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by a number of retail and institutional investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (11.34%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Rodney James Williams. View institutional ownership trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Which institutional investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock?

ZOM stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc.. View insider buying and selling activity for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?

One share of ZOM stock can currently be purchased for approximately $0.21.

How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $23.21 million. The company earns $-19,780,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?

The official website for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is www.zomedica.com.

How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.